Free Trial
NASDAQ:NRSN

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

NeuroSense Therapeutics logo
$0.96 -0.03 (-3.05%)
(As of 01:50 PM ET)

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

Key Stats

Today's Range
$0.91
$1.02
50-Day Range
$0.96
$1.35
52-Week Range
$0.51
$2.33
Volume
81,734 shs
Average Volume
257,778 shs
Market Capitalization
$13.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
13th Percentile Overall Score

NRSN MarketRank™: 

NeuroSense Therapeutics scored higher than 13% of companies evaluated by MarketBeat, and ranked 910th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NeuroSense Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroSense Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroSense Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about NeuroSense Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.63% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently increased by 62.49%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NeuroSense Therapeutics does not currently pay a dividend.

  • Dividend Growth

    NeuroSense Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.63% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently increased by 62.49%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NeuroSense Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NeuroSense Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.04% of the stock of NeuroSense Therapeutics is held by institutions.

  • Read more about NeuroSense Therapeutics' insider trading history.
Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRSN Stock News Headlines

NeuroSense Therapeutics Secures Continued Nasdaq Listing
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
NeuroSense Completes Key ALS Trial Phase
Neurosense Therapeutics Secures $30 Million Equity Deal
NeuroSense Therapeutics Advances ALS Drug Development Plans
See More Headlines

NRSN Stock Analysis - Frequently Asked Questions

NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of 2024. Since then, NRSN shares have increased by 22.3% and is now trading at $0.9603.
View the best growth stocks for 2024 here
.

NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

Top institutional shareholders of NeuroSense Therapeutics include XTX Topco Ltd (0.34%).

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE).

Company Calendar

Today
11/21/2024
Next Earnings (Estimated)
11/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRSN
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Net Income
$-11,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.14) per share

Miscellaneous

Free Float
9,922,000
Market Cap
$13.53 million
Optionable
Not Optionable
Beta
1.58
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:NRSN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners